CD44 and prostate cancer: Since treatment-emergent NEPC can occur as a result of androgen deprivation therapy [143], CD44-targeted NIR-PIT may play a role as a local therapy for non-metastatic or oligo-metastatic castration-resistant prostate cancer with neuroendocrine differentiation.